Information Provided By:
Fly News Breaks for February 16, 2017
AGIO
Feb 16, 2017 | 11:28 EDT
As previously reported, Janney Capital analyst Debjit Chattopadhyay upgraded Agios Pharmaceuticals to Buy from Neutral and increased his fair value estimate on the shares to $57 from $44, as he believes "commercially viable, differentiated oncology assets," such as Agios' enasidenib and ivosidenib, are likely to trade at a premium.
News For AGIO From the Last 2 Days
There are no results for your query AGIO